Advertisement
Screener

GREENLAND MINES LTD (GRML) Graph

GRML Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development $400.54K; Operating expenses $5.49M; Income tax (m); Net income -$3.69M.
  • 2026-03-31: Research and development $321.27K; Operating expenses $9.51M; Income tax (m); Net income -$13.86M.
  • 2025-09-30: Research and development $271.14K; Operating expenses $1.85M; Income tax (m); Net income -$2.90M.
  • 2025-06-30: Research and development $238.70K; Operating expenses $1.89M; Income tax (m); Net income -$4.09M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$400.54K$5.49M(m)-$3.69M
2026-03-31$321.27K$9.51M(m)-$13.86M
2025-09-30$271.14K$1.85M(m)-$2.90M
2025-06-30$238.70K$1.89M(m)-$4.09M
2025-03-31$0.00$1.59M(m)-$2.23M
2024-12-31$0.00*(m)(m)(m)
2024-09-30$0.00$2.87M(m)-$2.96M
2024-06-30$0.00$395.61K(m)-$451.64K
2024-03-31$0.00$672.04K$49.07K-$672.04K
2023-12-31(m)(m)$112.00K*-$126.47K
2023-09-30$0.00$123.74K$148.85K-$144.11K
2023-06-30$0.00$244.25K$173.95K-$264.39K
2023-03-31(m)(m)$255.77K$1.12M
2022-09-30(m)(m)$79.75K$731.12K
2022-06-30(m)(m)(m)-$208.83K
2022-03-31(m)(m)(m)-$5.01K
2021-09-30(m)(m)(m)-$16.00
2021-06-30(m)(m)(m)-$3.51K

Revenue and expense 6 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$721.81K$15.00M(m)-$17.54M
2025-06-30$238.70K$3.48M(m)-$6.33M
2024-06-30$0.00$817.65K(m)-$1.12M
2023-06-30$0.00$396.85K$429.72K-$436.87K
2022-06-30(m)(m)(m)-$213.84K

Revenue and expense 7 month

Period endNet income
2021-09-30(m)

Revenue and expense 9 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-09-30$509.85K$5.33M(m)-$9.22M
2024-09-30$0.00$3.69M(m)-$4.08M
2023-09-30$0.00$520.59K$578.58K-$580.98K
2022-09-30(m)(m)$79.75K$517.29K

Revenue and expense 10 month

Period endNet income
2021-12-31-$3.56K

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31$634.19K$7.15M(m)-$10.55M
2024-12-31$0.00$5.54M(m)-$6.15M
2023-12-31$0.00$631.32K$690.57K-$707.46K
2022-12-31(m)(m)$322.02K$1.23M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
Vericel Corp (VCEL)United States$2.011B93.97
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
NOVAVAX INC (NVAX)United States$1.748B-6.26
Hemab Therapeutics Holdings, Inc. (COAG)United States$1.672B
Immunocore Holdings plc (IMCR)$1.613B-90.43